Cargando…
Effect on Morbidity and Mortality of Direct Oral Anticoagulants in Patients With COVID-19
Autor principal: | Toubasi, Ahmad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917387/ https://www.ncbi.nlm.nih.gov/pubmed/35292148 http://dx.doi.org/10.1016/j.amjcard.2022.02.007 |
Ejemplares similares
-
Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
por: Navarro-Almenzar, Begoña, et al.
Publicado: (2021) -
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in
Morbidly Obese Patients: An Updated Literature Review
por: Zhao, Ying, et al.
Publicado: (2023) -
Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli
por: Lachant, Daniel J., et al.
Publicado: (2021) -
The use of direct acting oral anticoagulants in patients with COVID-19 infection
por: Aly, Ragia, et al.
Publicado: (2021) -
The efficacy and safety of out-hospital anticoagulation therapy with direct oral anticoagulant for COVID-19
por: Geng, Yu, et al.
Publicado: (2023)